PRKCB: Protein kinase C beta type
Calcium-activated, phospholipid- and diacylglycerol (DAG)- dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on PRKCB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Enzastaurin | Phase 3 | Eli Lilly | Small molecule | InhibitorProtein kinase C beta inhibitor | 0 |
| Ruboxistaurin | Phase 3 | Chromaderm, Inc. | Small molecule | InhibitorProtein kinase C beta inhibitor | 0 |
- Acute myeloid leukemia0.59
- Mast cell leukemia0.47
- Systemic mastocytosis0.47
- Ulcerative colitis0.47
- Mastocytosis0.46
- Neoplasm0.44
- Inflammatory bowel disease0.41
- Acute myeloid leukemia by FAB classification0.37
- Diffuse large B-cell lymphoma0.36
- Neuropathy0.35
- Ankylosing spondylitis0.34
- Psoriasis0.33
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3045, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P05771, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets